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Abstract
Background: Deprescribing is a partnership between practitioners, patients and caregivers. External characteristics
including age, comorbidities and polypharmacy are poor predictors of attitude towards deprescribing. This hospital-
based study aimed to describe the desire of patients and caregivers to be involved in medicine decision-making,
and identify attitudinal predictors of desire to try stopping a medicine.
Methods: Patients and caregivers recruited from seven Older People’s Medicine wards across two UK hospitals
completed the revised Patients’Attitudes Towards Deprescribing (rPATD) questionnaire. Patients prescribed
polypharmacy and caregivers involved in medication decision-making of such patients were eligible. A target of
150 patients and caregivers provided a 95% confidence interval of ±11.0% or smaller around rPATD item
agreement. Descriptive statistics characterised participants and rPATD responses. Responses to items regarding
desire to be involved in medication decision-making and desire to try stopping a medicine were used to address
the aims. Binary logistic regression provided the adjusted odds ratios (OR) for predictors of desire to try stopping a
medicine.
Results: Patient participants (N = 75) were a median (IQ) 87.0 (83.0, 90.0) years old and the median (IQ) number of
pre-admission medication was 8.0 (6.0, 10.0). Caregiver participants (N = 76) were a median (IQ) 70.0 (57.0, 83.0)
years old and the majority were a spouse (63.2%). For patients and caregivers respectively, the following were
reported: 58.7 and 65.8% wanted to be involved in medication decision-making; 29.3 and 43.5% reported a desire
to try stopping a medicine. Attitudinal predictors of low desire to try stopping a medicine for patients and
caregivers are a perception that there are no unnecessary prescribed medicines [OR = 0.179 (patients) and 0.044
(caregivers)] and no desire for dose reduction [OR = 0.199 (patients) and 0.024 (caregivers)]. A perception of not
being prescribed too many medicines also predicted low patient desire to try stopping a medicine [OR = 0.195].
Conclusion: A substantial proportion of patients and caregivers did not want to be involved medication decision-
making, however this should not result in practitioners dismissing deprescribing opportunities. The three diagnostic
indicators for establishing desire to try stopping a medicine are perceived necessity of the medicine,
appropriateness of the number prescribed medications and a desire for dose reduction.
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Background
Potentially inappropriate medicines (PIMs) offer more
risks than benefits and are associated with adverse out-
comes including morbidity, hospitalisation and mortality
[1]. A prospective study across six European hospitals
reported between 34.7 and 77.3% of older people were
prescribed a PIM on admission [2]. There is therefore a
need to review medicines to determine suitability for
discontinuation, a process termed ‘deprescribing’ [3].
While the prevalence of PIMs on hospital admission is
high [2], deprescribing practice is limited and reactive in
response to iatrogenic harm rather than proactive to
prevent future harm [4]. Given that deprescribing
requires an accurate medication history and monitoring
to observe response to medication withdrawal [5], an
admission to hospital where these two activities are
routine, provides an opportunity to develop a depre-
scribing intervention.
Prescribing should be based on a partnership as the
prescriber is the disease expert and the patient is the
expert on their illness [6]. It is therefore unsurprising
that patient engagement in decision-making is a
proposed essential component of deprescribing [5]. Con-
sultations between practitioners and patients are an
opportunity to determine whether deprescribing is ap-
propriate, agree strategies for ongoing monitoring and
establish the patient’s desire to try deprescribing [5].
Trials across multiple settings report up to half of older
patients decline deprescribing interventions [7–10].
Exploration of predictors for this lack of desire to depre-
scribe has focussed on external characteristics such as age,
gender and number of prescribed medications. A recent
retrospective analysis of hospital electronic medical
records reported that all external characteristics analysed,
including PIM prevalence, number of medicines at admis-
sion and comorbidities had no effect on patients’ willing-
ness to accept deprescribing [10]. It is unsurprising that
these characteristics do not predict desire to deprescribe
as there is a substantial body of evidence in the field of be-
havioural science confirming that a key predictor of
behaviour is attitude towards the behaviour, which is
poorly predicted by external characteristics [11–13]. Fur-
thermore, external demographic characteristics cannot be
changed thus contribute little to guiding physicians or
those developing deprescribing interventions. Identifica-
tion of attitudinal predictors of desire to deprescribe may
therefore provide modifiable targets for an intervention
targeting patients’ and caregiver’ behaviour. Such attitu-
dinal predictors are likely to be related to patients’ barriers
and enablers to deprescribing, which have been charac-
terised in a variety of settings [14]. Patient reported
barriers include perceived continued need for medicines,
fear of withdrawal effects and previous bad experiences.
Conversely, experience or fear of side effects, absence of
observable benefits and reduction in pill burden are
patient reported enablers. The extent to which these po-
tentially modifiable attitudinal factors predict desire to
deprescribe remains unknown.
Informal caregivers such as family members are in-
creasingly involved in medication decision-making. For
patients that are unable to participate in these decisions,
such as those living with cognitive impairment, care-
givers frequently assume sole responsibility [15, 16]. Fur-
thermore, caregivers influence engagement with
deprescribing by physicians and patients who are able to
participate in decision-making [14, 17]. Despite the wide
ranging influence exerted by caregivers on the depre-
scribing processes, their level of engagement with and
attitudinal factors influencing desire to deprescribe are
unknown.
Older peoples’ attitudes towards deprescribing have
been described using the Patients’ Attitudes Towards
Deprescribing questionnaire (PATD) [18–21]. The
majority of respondents in the reported studies indicate
being satisfied with existing medication whilst incongru-
ously, over 90% also indicate willingness to accept depre-
scribing proposed by a doctor. This high level of
willingness contrasts the significant proportion of partic-
ipants in deprescribing trials declining deprescribing
propositions [7–10]. This gap between reported willing-
ness and observed behaviour requires further explor-
ation. Given that willingness to accept deprescribing
proposed by a doctor has demonstrated limited variation
in responses, this may not provide the best data for
explaining this gap.
The revised Australian-validated Patients’ Attitudes
Towards Deprescribing questionnaire (rPATD) explores
factors that influence desire to deprescribe not captured
by the PATD. The rPATD items are grouped into the
four factors of burden of taking medication, appropriate-
ness of medication (perceived harms and benefits), con-
cerns about stopping the medication and level of
involvement in making decisions about medicines. The
appropriateness factor provides the new item “I would
like to try stopping one of my medicines to see how I
feel without it”. This item provides an indication of the
patient’s attitude towards their prescribed medication by
indicating their desire to try stopping a medicine.
Furthermore, given that a significant proportion of
previously reported deprescribing trials have been
pharmacist-led [22], this item may provide better data
for explaining the gap between reported willingness to
accept deprescribing proposed by a doctor and observed
declining of deprescribing propositions.
This hospital-based study aimed to describe the likely
desire of patients and caregivers to be involved in medi-
cine decision-making and, identify any attitudinal pre-
dictors of desire to try stopping a medicine.
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Methods
Questionnaire refinement and testing
With the author’s consent, minor adaptations were made
to the rPATD prior to UK use. People aged ≥65 years in
the UK are exempt from prescription charges thus an
item in the rPATD burden factor exploring views to-
wards paying for medication was rephrased to explore
perceptions of the National Health Service’s (NHS)
medication expenditure. The item was phrased “I feel
my medicines are value for money for the NHS” and
appropriate variation for caregivers. The burden factor
captures the burden, such as financial, on the individual
patient (or caregiver), therefore this re-rephrased item
relating to burden on the NHS no longer belongs to this
factor. For the purposes of data reporting, the
re-phrased question was presented separately from the
burden factor under the heading burden to the National
Health Service.
Face and content validity of the UK adapted rPATD
were assessed using cognitive interviews with older people
and caregivers. Cognitive interviewing allows evaluation of
how the target audience perceives survey instruments and
their constructs. This information is used to identify sur-
vey flaws and improve questions [23, 24]. Whilst there
were no reasons to anticipate UK participants experien-
cing difficulties completing the Australian-validated
rPATD, cognitive interviews were undertaken in light of
the minor adaptation and to ensure face and content val-
idity were retained in the UK context.
Cognitive interview participants self-completed the
adapted rPATD with a researcher present and a concur-
rent ‘think-aloud’ with verbal probing identified and ex-
plored problems with interpreting and answering items
[23, 24]. Participants were also asked whether any fac-
tors influencing attitudes towards deprescribing were
underrepresented in the rPATD. Cognitive interviews
continued until no further adaptations were deemed ne-
cessary as evidenced by participants reporting no prob-
lems with completing the rPATD.
Administration of the UK adapted rPATD to patients and
caregivers in hospital
Study sample and setting
Patients and visiting caregivers were independently
recruited (i.e. they were not paired) from seven Older
People’s Medicine (OPM) wards at one and two UK
hospitals respectively. Criteria for patients triaged to an
OPM ward were minimum age (ranging between 70 to
80 years across sites) and either multiple co-morbidities
or physical frailty.
All inpatients from OPM wards prescribed at least five
pre-admission medicines (polypharmacy [25]) were
eligible. The number of pre-admission medicines was
determined from the hospitals’ pharmacy medicines
reconciliation records, which use at least two sources of
information, such as a community pharmacy record and
a patient’s own report, to establish an accurate medica-
tion history. Patients unable to speak or read English,
deemed by the healthcare team as unable to provide
informed consent, inappropriate to approach for recruit-
ment for reasons such as being seriously unwell or
unable to make informed decisions about medicines
were excluded. For patients who were unable to provide
informed consent or make informed decisions about
medicines, any of their visitors during the study period
were screened as caregiver participants. Accordingly,
patients and caregivers were not paired.
All visitors self-reporting an unpaid role in managing
the medication of an inpatient satisfying the inclusion
criteria for the study’s patient participant arm were
eligible as caregivers. Caregivers unable to speak or read
English and aged < 18 years old were excluded.
Recruitment and survey administration
Patients were screened for eligibility and approached for
inclusion by an OPM doctor, nurse or pharmacist.
Patients expressing an interest were approached by a
researcher who provided an information leaflet and
answered questions. Written, informed consent was
obtained for rPATD administration and collection of
demographic information. The rPATD was self-completed
on an electronic tablet by patients at the bedside with a re-
searcher present to assist if necessary. Patient demograph-
ics and the number of pre-admission medicines were
recorded.
Visitors of OPM wards were screened by a research
nurse for eligibility to determine whether they were
caregivers self-reporting an unpaid role in managing the
medication of an OPM patient. Only one caregiver per
OPM patient was approached for recruitment as it was
deemed unethical by the study team’s patient and care-
giver members to approach several caregivers for one
patient. As no identifiable personal information was
collected from caregivers, consent was implied through
self-completion of the questionnaire. Caregivers who
agreed to participant were provided with a questionnaire
pack including an anonymous demographic information
collection form and the rPATD. Caregivers were invited
to self-complete the questionnaire and provide demo-
graphic information for themselves and their care recipi-
ent in addition to indicating their relationship with the
care recipient and the number of pre-admission medica-
tions. Caregivers were instructed to return the pack to a
member of ward staff.
Participants were asked to respond to the rPATD
reflecting on medication as prescribed prior to admis-
sion (pre-admission medicines) but in the context of
deprescribing in the hospital setting.
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Sample size
No participant data are reported for the rPATD to in-
form sample size estimation. Participant data from the
original PATD indicate a maximum distribution across
the response items of 65 to 35%, representing the ‘worst
case scenario’ in terms of precision [20]. This was re-
ported for the item “I feel that I am taking a large num-
ber of medications”. Accordingly, response for all other
items are estimated to a greater degree of precision.
Based on the 65 to 35% PATD response distribution, as-
suming a similar distribution for the rPATD and antici-
pated minimal adaptations required for UK use, a sample
of 75 participants per population provides a 95% confi-
dence interval (CI) of ±11.0% or smaller around the esti-
mates of agreement with each rPATD item. This sample
size is therefore appropriate for ensuring that there is no
overlap in CIs between the proportion of respondents
agreeing and disagreeing with an rPATD item.
Statistical analysis
Analyses were performed using IBM SPSS Statistics ver-
sion 23.0 for Windows. Descriptive statistics were used
to characterise the participants and rPATD responses.
Items are reported grouped under the four rPATD fac-
tors; burden, appropriateness, concerns about stopping
and involvement. Global item 1 captures willingness to
accept deprescribing proposed by a doctor and global
item 2 captures satisfaction with current medications.
The primary outcome of desire to try stopping a medi-
cine was the appropriateness question “I would like to
try stopping one of my medicines to see how I feel with-
out it” (patients) and “I would like the doctor to try
stopping one of my care recipient’s medicines to see
how they feel without it” (caregivers).
In order to identify respondents with a desire to try
stopping a medicine, responses to the primary outcome,
involvement item relating to likely desire to be involved
in medicine decision-making and the two global rPATD
questions were dichotomised into those in agreement
(agree and strongly agree) and those ambivalent or in
disagreement (strongly disagree, disagree and neither
agree nor disagree).
Backward binary logistic regression was performed be-
tween statements in the four factors and the primary
outcome. To identify perceived barriers predicting desire
to try stopping a medicine, responses to each statement
were dichotomised into those who disagreed that it was
a barrier (strongly disagree and disagree) and those who
were ambivalent or in agreement (neither agree nor dis-
agree, agree and strongly agree) that it was a barrier.
Variables with less than 5.0% distribution in responses
cross-tabulated with the primary outcome were excluded
as it was felt that these had insufficient variability to be
reliability modelled.
Results
Questionnaire testing and refinement
After three cognitive interviews with patients and care-
givers, no further recommendations for improving the
rPATD items were suggested. Patient participant’s ages
ranged between 69 and 73 years and two were male.
Patients were taking between five and 15 medicines. All
three caregiver participants were female aged between
28 and 54 years and, two of their care recipients were
female. Caregivers’ care recipients were taking between
five and 11 medicines.
No recommendations for improving the original
rPATD items were identified. However, the first partici-
pant, a caregiver, expressed difficulty with responding to
the adapted item regarding NHS spending on
medication, citing insufficient knowledge of the
cost-effectiveness of medicines. This in turn led to diffi-
culties with expressing a view on whether they felt medi-
cines were providing value for money to the NHS. The
participant acknowledged the relevance of exploring
views towards medication expenditure and suggested
rephrasing the item as follows: “I feel the NHS spends a
lot of money on my care recipient’s medicines”. The
proposed revision was accepted by the research team
and presented to subsequent participants, with appropri-
ate adaptation for the patient rPATD version. The
adapted item was acceptable to the remaining two care-
givers and three patients, thus no further refinements
were necessary. No additional factors potentially influen-
cing attitudes towards deprescribing not already present
in the rPATD were proposed. As face and content valid-
ity were demonstrated, no further adaptations to the
rPATD were necessary.
Administration of the adapted rPATD to patients and
caregivers in hospital
Figure 1 summarises recruitment of patients and care-
givers; the primary reason for patient ineligibility was be-
ing unable to provide informed consent. For caregivers,
non-involvement with medicines was the primary reason
for exclusion.
Patients
Recruitment of the target 75 patients from those eligible
produced a recruitment rate of 70.1% (95% CI: 52.7,
87.5). Patient participant demographics are provided in
Table 1.
Responses to the rPATD questionnaire
Table 2 illustrates patients’ rPATD responses. Agreement
with deprescribing proposed by a doctor was high, with
97.4% (95% CI 93.8–100.0) agreeing with global item 1
(If my doctor said it was possible I would be willing to
stop one or more of my regular medicines). Conversely,
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only 29.3% (95% CI 19.0–39.6) agreed with the primary
outcome item (I would like to try stopping one of my
medicines to see how I feel without it). A further 92.0%
(95% CI 85.9–98.1) agreed with global item 2 (Overall, I
am satisfied with my current medicines), indicating high
satisfaction with current medications. Just over half
(58.7% (95% CI 47.6–69.8)) of patients expressed a desire
to be involved in medication-decision making in
response to the relevant involvement item (I like to be
involved in making decisions about my medicines with
my doctors).
Regression analysis
Items from all four factors were entered into the re-
gression analysis. The resulting model predicted
62.9% (Negelkerke R2) of the variance and the Hos-
mer and Lemeshow goodness-of-fit test implied the
model’s estimates fit the data to an acceptable level
(p = 0.238). rPATD items predicting patients’ lack
desire to try stopping a medicine are provided in
Table 3. The full patient regression analysis is pro-
vided in Additional file 1: Table S1.
Caregivers
The caregiver arm over recruited by one participant
producing a recruitment rate of 67.2% (95% CI: 49.9,
84.5) for the 76 caregivers who completed the ques-
tionnaire. Caregiver and care recipient demographics
are provided in Table 1.
Fig. 1 Participant flow
Table 1 Patient, caregiver and care recipient demographics
Patient participants
Median (IQ) age 87.0 (83.0, 90.0)
Number (%) female 34 (45.3)
Median (IQ) number of pre-admission medicines 8.0 (6.0, 10.0)
Caregiver participants
Relationship to care recipient
Number (%) spouse or partner 35 (46.1)
Number (%) non-spouse or partner relative 41 (53.9)
Median (IQ) caregiver age 70.0 (57.0, 83.0)
Median (IQ) care recipient age 86 (83.0, 89.0)
Number (%) female caregivers 47 (61.8)
Number (%) female caregivers 48 (63.2)
Median (IQ) number of pre-admission medicines
prescribed to care recipient
8.0 (6.0, 10.3)
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Responses to the rPATD questionnaire
Table 4 illustrates caregivers’ rPATD responses. Agree-
ment with deprescribing proposed by a doctor was high,
with 76.3% (95% CI 66.7–85.9) of caregivers agreeing
with global item 1 (If their doctor said it was possible I
would be willing to stop one or more of my care recipi-
ent’s medicines). Conversely, only 43.5% (95% CI 32.4–
54.6) agreed with the primary outcome (I would like the
doctor to try stopping one of my care recipient’s medi-
cines to see how they feel without it). A further 80.3%
Table 2 Patients’ responses to the rPATD questionnaire
Item Strongly
disagree
Number (%)
Disagree
Number
(%)
Neither agree nor
disagree Number
(%)
Agree
Number
(%)
Strongly
agree
Number (%)
Burden to the National Health Service
I feel the National Health Service (NHS) spends a lot of money on
my medicines
1 (1.3) 4 (5.3) 7 (9.3) 44 (58.7) 19 (25.3)
Burden
Taking my medicines every day is very inconvenient 22 (29.3) 37 (49.3) 4 (5.3) 11 (14.7) 1 (1.3)
I feel that I am taking a large number of medicines 6 (8.0) 26 (34.7) 7 (9.3) 27 (36.0) 9 (12.0)
I feel that my medicines are a burden to me 21 (28.0) 38 (50.7) 5 (6.7) 7 (9.3) 4 (5.3)
Sometimes I think I take too many medicines 11 (14.7) 26 (34.7) 7 (9.3) 23 (30.7) 8 (10.7)
Appropriateness
I feel that I may be taking one or more medicines that I no longer
need
13 (17.3) 29 (38.7) 8 (10.7) 17 (22.7) 8 (10.7)
I would like to try stopping one of my medicines to see how I
feel without ita
14 (18.7) 30 (40.0) 9 (12.0) 16 (21.3) 6 (8.0)
I would like my doctor to reduce the dose of one or more of my
medicines
13 (17.3) 32 (42.7) 15 (20.0) 11 (14.7) 4 (5.3)
I think one or more of my medicines may not be working 12 (16.0) 26 (34.7) 22 (29.3) 13 (17.3) 2 (2.7)
I believe one or more of my medicines may be currently giving
me side effects
21 (28.0) 29 (38.7) 4 (5.3) 15 (20.0) 6 (8.0)
Concerns about stopping
I would be reluctant to stop a medicine that I had been taking for
a long time
7 (9.3) 35 (46.7) 5 (6.7) 21 (28.0) 7 (9.3)
If one of my medicines was stopped, I would be worried about
missing out on future benefits
14 (18.7) 28 (37.3) 5 (6.7) 25 (33.3) 3 (4.0)
I get stressed whenever changes are made to my medicines 17 (22.7) 39 (52.0) 7 (9.3) 10 (13.3) 2 (2.7)
If my doctor recommended stopping a medicine, I would feel
that he/she was giving up on me
30 (40.0) 31 (41.3) 2 (2.7) 8 (10.7) 4 (5.3)
I have had a bad experience when stopping a medicine before 53 (70.7) 11 (14.6) 5 (6.7) 4 (5.3) 2 (2.7)
Involvement
I have a good understanding of the reasons I was prescribed each
of my medicines
6 (8.0) 3 (4.0) 6 (8.0) 38 (50.7) 22 (29.3)
I know exactly what medicines I am currently taking, and/or I
keep an up-to-date list of my medicines
5 (6.7) 10 (13.3) 3 (4.0) 28 (37.3) 29 (38.7)
I like to know as much as possible about my medicines 3 (4.0) 10 (13.3) 5 (6.7) 35 (46.7) 22 (29.3)
I like to be involved in making decisions about my medicines
with my doctors
6 (8.0) 19 (25.3) 6 (8.0) 23 (30.7) 21 (28.0)
I always ask my doctor, pharmacist or other healthcare
professional if there is something I don’t understand about my
medicines
1 (1.3) 13 (17.3) 2 (2.7) 33 (44.0) 26 (34.7)
Global
If my doctor said it was possible I would be willing to stop one or
more of my regular medicines
1 (1.3) 1 (1.3) 0 50 (66.7) 23 (30.7)
Overall, I am satisfied with my current medicines 0 1 (1.3) 5 (6.7) 49 (65.3) 20 (26.7)
aPrimary outcome item
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(95% CI 71.3–89.3) agreed with global item 2 (Overall, I
am satisfied with my care recipient’s current medicines),
indicating high satisfaction with current medications.
Approximately two thirds of caregivers (65.8% (95% CI
55.1–76.5)) expressed a desire to be involved in
medication-decision making in response to the relevant
involvement item (I like to be involved in making deci-
sions about my care recipients medicines with their
doctors).
Regression analysis
Item 1 from burden and 2 from involvement were not
entered into the regression due to insufficient distribu-
tion across responses. All remaining questions across
the factors were entered into the binary logistic regres-
sion analysis with the primary outcome. The resulting
model predicted 70.1% of the variance (Negelkerke R2)
and the Hosmer and Lemeshow goodness-of-fit test im-
plied the model’s estimates fit the data to an acceptable
level (p = 0.852). rPATD items predicting caregivers’ lack
of desire to try stopping a medicine are provided in
Table 3. The full caregiver regression analysis is provided
in Additional file 2: Table S2.
Discussion
Engagement of patients and caregivers is a core compo-
nent of deprescribing, yet a substantial proportion indi-
cated limited desire to be involved in medication
decision-making. Furthermore, the low desire to try
stopping a medicine is in agreement with the substantial
proportions of participants declining deprescribing in
the trial environment [7–10]. However, patients and
caregivers overwhelmingly report agreement with depre-
scribing proposed by a doctor. Practitioners should not
therefore dismiss deprescribing opportunities due to
patients and caregivers choosing to be less involved in
decision-making. The three diagnostic indicators for
establishing desire to try stopping a medicine are per-
ceptions of the number and necessity of medicines and,
a desire for dose reduction. These may also assist physi-
cians with targeting relevant attitudinal predictors dur-
ing deprescribing discussions.
Given similarities between the two English-speaking
nations, minimal adaptations to the Australian rPATD
were required before UK use. The item exploring burden
of paying for medication was adapted to reflect the UK
context. Whilst the sample size estimation was based on
PATD data, the observed variation in responses to the
global items was comparable, yielding confidence inter-
vals equal to or narrower than predicted. The high con-
sent rates afford some confidence in the generalisability
of the findings to the populations of the hospitals at
which the research was conducted. The presence of a
researcher to support patients self-completing the
rPATD may have biased responses. However, similarities
with the caregiver rPATD responses indicate that
researcher presence is unlikely to have unduly influenced
the findings.
Half of potentially eligible patients were excluded due to
inability to participate in medication decision-making. In-
clusion of caregivers therefore provides representation of
this previously under-researched population [18–20, 26].
The patient participant population is comparable to previ-
ous PATD studies [18–20, 26] and to a pan European
study evaluating older people’s hospital admissions [2].
The caregiver population was comparable with a US study
exploring treatment preferences of caregivers involved in
medication decision-making [15]. These similarities indi-
cate that the study findings may be generalisable beyond
the two hospital study sites.
Similar to previous patient PATD responses in the out-
patient clinic, acute hospital and care home settings, the
global rPATD items in the present study demonstrated
little variation, with the majority of respondents agreeing
with deprescribing proposed by a doctor whilst also be-
ing satisfied with current medicines [18–20, 26]. There
was, however, greater variation in responses to the items
relating to patients’ and caregivers’ desire to be involved
Table 3 rPATD items predicting patients’ and caregivers’ lack of desire to try stopping a medicine
Predictor rPATD item Unadjusted odds ratio
(95% confidence interval)
p-value Adjusted odds ratio
(95% confidence interval)
p-value
Patients
Sometimes I think I take too many medicines 0.072 (0.023–0.231) < 0.001 0.195 (0.045–0.841) 0.028
I feel that I may be taking one or more medicines that I no longer need 0.075 (0.025–0.229) < 0.001 0.179 (0.044–0.726) 0.016
I would like my doctor to reduce the dose of one or more of my
medicines
0.066 (0.021–0.206) < 0.001 0.199 (0.050–0.787) 0.021
Caregivers
I feel that the person that I care for may be taking one or more medicines
that they no longer need
0.092 (0.030–0.279) < 0.001 0.044 (0.006–0.310) 0.002
I would like the doctor to reduce the dose of one or more of my
care recipient’s medicines
0.025 (0.007–0.094) < 0.001 0.024 (0.004–0.137) < 0.001
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in medicine decision-making. This agrees with the exist-
ing literature in relation to some older people expressing
preference for a passive role in decision-making [27–31]
and may also be true of caregivers, who were similarly
older in age [32].
Medication expenditure was acknowledged as a bur-
den to the NHS by the majority of respondents, however
this did not predict desire to try stopping a medicine.
Patients did not consider their medications a burden as
evidenced by no items in the burden factor attracting
general agreement. Caregiver responses were similar,
however the majority felt care recipients were taking a
large number of medicines.
The appropriateness factor demonstrated greatest di-
vergence between patients and caregivers. The majority
of patients perceived their medicines were appropriate,
Table 4 Caregivers’ responses to the rPATD questionnaire
Item Strongly
disagree
Number %
Disagree
Number
%
Neither agree nor
disagree Number
%
Agree
Number
%
Strongly
agree
Number %
Burden to the National Health Service
I feel the National Health Service (NHS) spends a lot of money on my
care recipient’s medicines
0 5 (6.6) 28 (36.8) 26 (34.2) 17 (22.4)
Burden
I feel that the person I care for is taking a large number of medicines 4 (5.3) 14 (18.4) 18 (23.7) 31 (40.8) 9 (11.8)
I feel that my care recipient’s medicines are a burden to them 8 (10.5) 37 (48.7) 14 (18.4) 16 (21.1) 1 (1.3)
Sometimes I think the person I care for takes too many medicines 8 (10.5) 21 (27.6) 23 (30.3) 21 (27.6) 3 (3.9)
Appropriateness
I feel that the person that I care for may be taking one or more
medicines that they no longer need
4 (5.3) 22 (28.9) 22 (28.9) 25 (32.9) 3 (3.9)
I would like the doctor to try stopping one of my care recipient’s
medicines to see how they feel without ita
7 (9.2) 22 (28.9) 14 (18.4) 29 (38.2) 4 (5.3)
I would like the doctor to reduce the dose of one or more of my care
recipient’s medicines
7 (9.2) 22 (28.9) 29 (38.2) 16 (21.1) 2 (2.6)
I think one or more of my care recipient’s medicines may not be
working
5 (6.6) 22 (28.9) 32 (42.1) 17 (22.4) 0
I believe one or more of my care recipient’s medicines may be
currently giving them side effects
6 (7.9) 25 (32.9) 18 (23.7) 23 (30.3) 4 (5.3)
Concerns about stopping
I would be reluctant to stop one of my care recipient’s medicines that
they had been taking for a long time
2 (2.6) 20 (26.3) 13 (17.1) 35 (46.1) 6 (7.9)
I get stressed whenever changes are made to my care recipient’s
medicines
16 (21.1) 28 (36.8) 19 (25.0) 13 (17.1) 0
I feel that if I agreed to stopping one of my care recipient’s medicines
then this is giving up on them
15 (19.7) 29 (38.2) 16 (21.1) 13 (17.1) 3 (3.9)
The person that I care for has had a bad experience when stopping a
medicine before
43 (56.6) 22 (28.9) 6 (7.9) 5 (6.6) 0
Involvement
I know exactly what medicines the person that I care for is currently
taking and/or I have an up-to-date list of their medicines
0 12 (15.8) 3 (3.9) 41 (53.9) 16 (21.1)
I like to know as much as possible about my care recipient’s medicines 0 3 (3.9) 8 (10.5) 39 (51.3) 22 (28.9)
I like to be involved in making decisions about my care recipients
medicines with their doctors
2 (2.6) 10 (13.2) 10 (13.2) 33 (43.4) 17 (22.4)
I always ask the doctor, pharmacist or other healthcare professional if
there is something I don’t understand about my care recipient’s
medicines
1 (1.3) 10 (13.2) 7 (9.2) 39 (51.3) 15 (19.7)
Global
If their doctor said it was possible I would be willing to stop one or
more of my care recipient’s medicines
2 (2.6) 1 (1.3) 14 (18.4) 50 (65.8) 8 (10.5)
Overall, I am satisfied with my care recipient’s current medicines 2 (2.6) 2 (2.6) 10 (13.2) 51 (67.1) 10 (13.2)
aPrimary outcome item
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whereas caregivers were ambivalent. This may be due to
caregivers feeling that they lack understanding of their
care recipient’s treatments [27].
Whilst there is qualitative literature indicating that
deprescribing generates concerns for patients [17], the
majority of patient respondents indicated that they did
not hold concerns about stopping medication. This may
be due to differences between actively inviting people to
generate potential concerns versus inviting an opinion
on specific concerns as in the present study [33]. Care-
giver responses were similar to patients’, however resist-
ance to deprescribing long-standing medication was
conveyed but did not predict lack desire to try stopping
a medicine. Physicians report reluctance to propose
deprescribing for fear of patients perceiving this as with-
drawal of care [14]; the present study suggests neither
patients nor caregivers hold this view.
Some caution should be applied to this message, as
whilst the majority of respondents agreed with depre-
scribing proposed by a doctor, they also reported content
with existing medication. This potentially reflects a
desire to conform, which may lead to agreement with a
doctor’s recommendation to deprescribe despite con-
cerns [31] and reluctance to report adverse outcomes
such as return of symptoms [30].
The reported preference for a passive role in medica-
tion decision-making by older people in the literature
[27] was expressed by some patients and caregivers in
their responses to items in the involvement factor.
Whilst items relating to the passive behaviour of know-
ledge acquisition regarding prescribed medicines
attracted high agreement, the item relating to liking to
be involved in decisions about medicines was lower.
The attitudinal predictors of desire to try stopping a
medicine for both patients and caregivers are perceived
necessity and a desire for dose reduction. As both items
are from the appropriateness factor, this may represent a
limitation of using an appropriateness item as the pri-
mary outcome. However, this could also suggest that at-
titude towards the appropriateness of medication is the
most suitable target for a behaviour change intervention.
Additionally, the predictive ability of the burden item re-
garding taking too many medicines for patients and not
for caregivers suggests that a patients’ perceived burden
of medicine taking is an important indicator of their de-
sire to try stopping a medicine.
As the target behaviour is deprescribing and a key pre-
dictor of deprescribing is attitude towards deprescribing
[11–13], the three attitudinal predictors are potential
intervention targets. The finding that perceived medica-
tion necessity and a desire for dose reduction are predic-
tors of both patients’ and caregivers’ desire to try
stopping a medicine may offer efficiencies for interven-
tion design. Behaviour change techniques offer an
evidence-based approach to modifying attitudes towards
a behaviour. For example, a practitioner may identify
that a patient is prescribed an inappropriate medicine
who is ambivalent to deprescribing. The present study
indicates that one or more of three attitudinal predictors
of desire to try stopping a medicine may alter this am-
bivalence. For example, the patient’s perception that they
are not taking too many medicines can be targeted with
the evidence-based behaviour change technique ‘infor-
mation about emotional consequences’ [34, 35]. This
theory-based approach to changing patients’ attitude
towards deprescribing has been reported in the
EMPOWER trial, which includes the behaviour change
technique ‘information about health consequences’ [36].
Conclusions
Patients and caregivers overwhelmingly report agreement
with deprescribing proposed by a doctor yet vary in the
extent to which they want to be involved in medicine
decision-making. Practitioners should not therefore dis-
miss deprescribing opportunities due to patients and care-
givers choosing to be less involved in decision-making.
Three attitudinal predictors of reported desire to try stop-
ping a medicine provide modifiable targets for developing
a hospital deprescribing intervention targeting patients’
and caregivers’ behaviour. Future work should focus on
identifying and testing evidence based behaviour change
techniques targeting these attitudinal predictors for inclu-
sion in deprescribing interventions.
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